Celiac Disease Panel
Label Mnemonic: | CDP |
Epic code: | LAB8840 |
Order form: | Laboratory Requisition |
Supply order: | Supply Order Form |
Billing: | Billing Policies |
CPT code: |
83520 Gliadin (Deamidated) IgA Antibody 83520 Gliadin (Deamidated) IgG Antibody 83520 Tissue Transglutaminase IgA Antibody 83520 Tissue Transglutaminase IgG Antibody |
Specimen(s):
Plasma
Collection Medium:
![]() |
Plasma Separator Tube 4.5 mL |
Minimum:
Adult - 3 mL plasma separator tube
Pediatric - two Microtainer® devices
Pediatric - two Microtainer® devices
Turn Around Time:
3 hours (upon receipt in laboratory)
Reference Range:
Gliadin (Deamidated) IgA: Negative: <15 U/mL Positive: 15 U/mL or greater The deamidated gliadin (DPG) IgA reflexes automatically to DPG IgG if the total IgA is too low. In these cases, DPG IgA will be resulted as "LOW IGA" and the charges credited. Tissue Transglutaminase IgA: Negative: <15 U/mL Positive: 15 U/mL or greater The tissue transglutaminase (TTG) IgA reflexes automatically to TTG IgG if the total IgA is too low. In these cases, TTG IgA will be resulted as "LOW IGA" and the charges credited.
Comments:
Celiac disease or gluten-sensitive enteropathy is an immune- mediated disorder that primarily affects the gastrointestinal tract and is characterized by chronic inflammation of the small intestine mucosa, which may result in atrophy of intestinal villi, malabsorption and a variety of clinical manifestations. It is caused by a pathological intolerance to gliadin, the alcohol-soluble fraction of gluten in wheat, rye and barley. Celiac disease manifests at any age with a peak onset in early childhood. Recent studies now suggest that its prevalence is in the range of 0.5 to 1.0% of the U.S. population with certain populations having an increased prevalence of celiac disease. Celiac disease is also associated with selective IgA deficiency and autoimmune disorders. The US incidence rate is 1:130, which is similar to European countries. Diagnosis of celiac disease is based on a combination of clinical symptoms and the following factors: IgA and/or IgG antibodies to tissue transglutaminase (TTG) IgA and/or IgG antibodies to deamidated gliadin Endomysial IgA and/or IgG antibodies Human leukocyte antigen (HLA)-DQ2 or DQ8 genotypes Biopsy of the small intestine (demonstrating flat mucosa) Or a patient's satisfactory response to a gluten-free diet (GFD). IgA deficiency is more common in the celiac disease (2-3%) versus the average population (0.1-0.2%). Therefore, it is recommended that IgG antibodies to deamidated gliadin be determined if there is total IgA deficiency. Deamidated gliadin IgA has sensitivity and specificity for celiac disease diagnosis of approximately 87% and 97%, respectively. TTG IgA has sensitivity and specificity for celiac disease diagnosis of approximately 95% and 99%, respectively, and is thus a front-line test in the diagnostic work-up of celiac disease. References: 1. The National Institutes of Health (NIH) Consensus Development Conference on Celiac Disease, NIH Consensus Development Conference Statement, June 28-30, 2004. 2. van der Windt, et al. Diagnostic Testing for Celiac Disease Among Patients with Abdominal Symptoms: a Systematic Review. JAMA May 2010, 303(17);1738-46. 3. G. Holmes, C. Catassi, A. Fasano. Fast Facts: Celiac Disease. 2nd Edition; August 2009, 57-63. 4. Rashtak S., Ettore M., Homberger H., Murray J. Comparative Usefulness of Deamidated Gliadin Antibodies in the Diagnosis of Celiac Disease. Clin Gastroenterol Hepatol April 2008, 6(4); 426- 32. 5. Green, P.H., Jones. R. Celiac Disease: A Hidden Epidemic. 2006, 45-48. 6. Van Meensel B, Hiele M, Hoffman I, et al. 2004. Diagnostic accuracy of ten second-generation (human) tissue transglutaminase antibody assays in celiac disease. Clin Chem. 50: 2125-35.
Methodology:
Gliadin IgA, Gliadin IgG, Tissue Transglutaminase IgA, and Tissue
Transglutaminase IgG: Multiplex Flow Immunoassay
Sample Processing:
Centrifuge at a speed and time necessary to get barrier separation
of plasma/serum and cells within 1 hour of collection. Send specimen
in original tube. Do Not transfer to another tube.
Each sample must be labeled with at least TWO full patient identifiers (First/Last Name & DOB are sufficient for non-UIHC affiliated clients) to avoid sample rejection/delays.
Each sample must be labeled with at least TWO full patient identifiers (First/Last Name & DOB are sufficient for non-UIHC affiliated clients) to avoid sample rejection/delays.
Sample Storage:
Refrigerate.
All sample storage requirements are intended for delivery to UIHC within 24 hours of collection for testing. If samples won't arrive in this time period, please call the UIHC Core Lab for alternative storage/shipping instructions (319-356-3527).
All sample storage requirements are intended for delivery to UIHC within 24 hours of collection for testing. If samples won't arrive in this time period, please call the UIHC Core Lab for alternative storage/shipping instructions (319-356-3527).
Transport Instructions:
Place labeled specimen into zip-lock type biohazard bag; seal
bag.
Place completed requisition into outside pocket of bag.
Transport in cooler with refrigerated coolant packs.
Place completed requisition into outside pocket of bag.
Transport in cooler with refrigerated coolant packs.
See also:
Gliadin (Deamidated) IgA Antibody, Plasma
Gliadin (Deamidated) IgG Antibody, Plasma
Tissue Transglutaminase IgA, Plasma
Tissue Transglutaminase IgG, Plasma
Gliadin (Deamidated) IgA Antibody, Plasma
Gliadin (Deamidated) IgG Antibody, Plasma
Tissue Transglutaminase IgA, Plasma
Tissue Transglutaminase IgG, Plasma